DK1760088T3 - Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler - Google Patents

Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler

Info

Publication number: DK1760088T3
Authority: DK; Denmark
Prior art keywords: molecules; tumour; present; relates; hla
Prior art date: 2005-09-05

Application number

DK05019254T

Other languages

English (en)

Inventor

Joern Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2008-06-09

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2008-06-09 Application granted granted Critical

2008-06-09 Publication of DK1760088T3 publication Critical patent/DK1760088T3/da

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
210000000265 leukocyte Anatomy 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
230000001024 immunotherapeutic effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
239000008186 active pharmaceutical agent Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05019254T 2005-09-05 2005-09-05 Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler DK1760088T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number	Publication Date
DK1760088T3 true DK1760088T3 (da)	2008-06-09

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DK07007914.0T DK1806358T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK05019254T DK1760088T3 (da)	2005-09-05	2005-09-05	Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
DK07007915.7T DK1806359T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK09011319.2T DK2135878T3 (da)	2005-09-05	2006-09-05	Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK06791838.3T DK1922335T3 (da)	2005-09-05	2006-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK07007914.0T DK1806358T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK07007915.7T DK1806359T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK09011319.2T DK2135878T3 (da)	2005-09-05	2006-09-05	Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK06791838.3T DK1922335T3 (da)	2005-09-05	2006-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Country Status (23)

Country	Link
US (6)	US10196432B2 (da)
EP (6)	EP1806358B1 (da)
JP (1)	JP5627180B2 (da)
KR (3)	KR101386790B1 (da)
CN (3)	CN105440119A (da)
AT (5)	ATE461215T1 (da)
AU (2)	AU2006289290B2 (da)
BR (1)	BRPI0615462A2 (da)
CA (2)	CA2929252A1 (da)
CY (5)	CY1107973T1 (da)
DE (4)	DE602005005196T2 (da)
DK (5)	DK1806358T3 (da)
EA (1)	EA013876B1 (da)
ES (5)	ES2341295T3 (da)
HK (1)	HK1220709A1 (da)
HR (2)	HRP20100128T1 (da)
NO (1)	NO340870B1 (da)
NZ (2)	NZ588813A (da)
PL (5)	PL1806359T3 (da)
PT (5)	PT1760088E (da)
SI (5)	SI1806359T1 (da)
UA (1)	UA98295C2 (da)
WO (1)	WO2007028574A2 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1806358B1 (en) *	2005-09-05	2010-03-17	Immatics Biotechnologies GmbH	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
DK2183361T3 (en)	2007-07-27	2015-07-27	Immatics Biotechnologies Gmbh	Novel immunotherapy against brain tumors
BRPI0814140A2 (pt)	2007-07-27	2017-03-28	Immatics Biotechnologies Gmbh	composição de peptídeos associados a tumor e vacina anticâncer relacionada
BRPI0813626A2 (pt)	2007-07-27	2014-12-23	Immatics Biotechnologies Gmbh	Epitopos imunogênicos para a imunoterapia
US8455444B2 (en) *	2007-08-20	2013-06-04	Oncotherapy Science, Inc.	CDH3 peptide and medicinal agent comprising the same
EP2215111B1 (en)	2007-11-01	2016-03-16	Mayo Foundation For Medical Education And Research	Hla-dr binding peptides and their uses
ES2554981T3 (es)	2008-03-27	2015-12-28	Immatics Biotechnologies Gmbh	Nueva inmunoterapia contra tumores neuronales y cerebrales
DE602008000891D1 (de)	2008-04-30	2010-05-12	Immatics Biotechnologies Gmbh	Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr)	2008-05-14	2018-06-29	Immatics Biotechnologies Gmbh	Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
RS53782B1 (sr)	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2010085879A1 (en) *	2009-01-28	2010-08-05	Industrial Technology Research Institute	Urine and serum biomarkers associated with diabetic nephropathy
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
SG191154A1 (en)	2010-12-14	2013-07-31	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9987308B2 (en) *	2011-03-23	2018-06-05	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
HRP20211852T1 (hr)	2013-08-05	2022-03-18	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc
TWI777194B (zh)	2013-08-05	2022-09-11	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
HRP20191671T1 (hr)	2014-05-09	2019-12-13	Immatics Biotechnologies Gmbh	Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
PL3545965T3 (pl)	2014-12-23	2021-12-27	Immatics Biotechnologies Gmbh	Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi)	2015-03-27	2024-02-07	Immatics Biotechnologies Gmbh	Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
CA2989483A1 (en) *	2015-06-19	2016-12-22	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3919507A3 (en)	2015-07-01	2022-01-12	Immatics Biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20170579A (es)	2015-07-06	2018-05-25	Immatics Biotechnologies Gmbh	Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI796642B (zh)	2015-08-28	2023-03-21	德商英麥提克生物技術股份有限公司	用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
MY198087A (en)	2015-10-05	2023-07-31	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL298653A (en)	2015-12-11	2023-01-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides for use in immunotherapy against several types of cancer
KR102883915B1 (ko)	2015-12-16	2025-11-18	시애틀 프로젝트 코포레이션	신생항원 동정, 제조, 및 용도
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN116375797A (zh)	2016-03-01	2023-07-04	伊玛提克斯生物技术有限公司	用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
CR20180519A (es) *	2016-03-31	2019-03-05	Neon Therapeutics Inc	Neoantígenos y métodos de su uso
KR102411975B1 (ko)	2016-04-06	2022-06-22	이매틱스 바이오테크놀로지스 게엠베하	Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
CR20200608A (es)	2016-04-21	2021-01-20	Immatics Biotechnologies Gmbh	INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
BR112018070873A2 (pt)	2016-04-21	2019-02-05	Immatics Biotechnologies Gmbh	imunoterapia contra melanoma e outros cânceres
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
PL3469361T3 (pl) *	2016-06-10	2025-02-03	Gadeta B.V.	Nowy sposób identyfikacji łańcuchów receptora limfocytu t delta (lub limfocytu t gamma) lub części tych łańcuchów, które pośredniczą w odpowiedzi przeciwnowotworowej lub przeciwzakaźnej
TWI796299B (zh) *	2016-08-26	2023-03-21	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
TWI796314B (zh)	2017-01-27	2023-03-21	德商英麥提克生物技術股份有限公司	用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
PE20191248A1 (es)	2017-01-27	2019-09-18	Immatics Biotechnologies Gmbh	Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
EA201991444A1 (ru)	2017-01-27	2019-12-30	Имматикс Байотекнолоджиз Гмбх	Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
EP3576767A4 (en) *	2017-02-06	2020-12-02	Academia Sinica	RECOMBINATED PROTEINS AND THEIR USES
US11427614B2 (en)	2017-04-10	2022-08-30	Immatics Biotechnologies Gmbh	Peptides and combination thereof for use in the immunotherapy against cancers
BR112019021094A2 (pt)	2017-04-10	2020-05-12	Immatics Biotechnologies Gmbh	Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres
WO2018189152A2 (en)	2017-04-10	2018-10-18	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
EP3609530A1 (en)	2017-04-10	2020-02-19	Immatics Biotechnologies GmbH	Peptides and combination thereof for use in the immunotherapy against cancers
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
CN119080881A (zh)	2017-07-07	2024-12-06	伊玛提克斯生物技术有限公司	用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
MX2020002891A (es)	2017-09-18	2021-01-08	S & P Ingredient Dev Llc	Sustituto de sal bajo en sodio con cloruro de potasio.
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko)	2017-11-22	2026-01-15	시애틀 프로젝트 코포레이션	신생항원에 대한 접합 에피토프 제시 감소
JP7470640B2 (ja)	2018-02-09	2024-04-18	イマティクスユーエス，アイエヌシー．	Ｔ細胞を製造する方法
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL276839B1 (en) *	2018-02-27	2026-05-01	Gritstone Bio Inc	Neoantigen identification using pan-allelic models
EP3539562A1 (en) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immunotherapeutic peptides
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en)	2018-09-17	2024-04-02	Immatics Biotechnologies Gmbh	B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
US20200384028A1 (en)	2019-06-06	2020-12-10	Immatics Biotechnologies Gmbh	Sorting with counter selection using sequence similar peptides
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
MX2022001209A (es) *	2019-07-30	2022-05-03	Univ Health Network	Receptores de linfocitos t y métodos de uso de estos.
EP3827840A1 (en) *	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp peptide variant and uses thereof
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
CN120712104A (zh) *	2022-10-14	2025-09-26	广东天科雅生物医药科技有限公司	针对神经胶质瘤的肽疫苗及其用途
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (da) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da)	1978-12-22	1997-04-14	Biogen Inc	Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) *	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
EP0636175A1 (en) *	1992-04-03	1995-02-01	La Jolla Cancer Research Foundation	Decorin fragments and methods of inhibiting cell regulatory factors
CA2142007C (en) *	1992-08-11	2007-10-30	Robert Glen Urban	Immunomodulatory peptides
WO1995011923A1 (en) *	1993-10-29	1995-05-04	Dana-Farber Cancer Institute, Inc.	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
NZ290089A (en)	1994-07-27	1999-05-28	Queensland Inst Med Res	Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
CA2243235C (en)	1996-01-17	2010-08-10	Imperial College Innovations Limited	Immunotherapy using cytotoxic t lymphocytes (ctl)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
WO1998031818A2 (en) *	1997-01-21	1998-07-23	Human Genome Sciences, Inc.	Tace-like and matrilysin-like polypeptides
US6316213B1 (en)	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
WO1999019477A1 (de) *	1997-10-15	1999-04-22	Forssmann Wolf Georg	Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
US20020081590A1 (en) *	2000-02-04	2002-06-27	Aeomica, Inc.	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US7118853B2 (en) *	2000-07-26	2006-10-10	Applied Genomics, Inc.	Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
AU2001295582A1 (en)	2000-12-20	2002-07-01	GlaxoSmithKline Biologicals (s.a.)	Tumour-related antigens
WO2002078516A2 (en)	2001-03-30	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
AU2002322280A1 (en) *	2001-06-21	2003-01-21	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7087727B2 (en) *	2001-08-13	2006-08-08	Dana-Farber Cancer Institute, Inc.	Periostin-based diagnostic assays
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
WO2003068940A2 (en) *	2002-02-14	2003-08-21	Curagen Corporation	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2004014867A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
CA2500687A1 (en) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
JP2007504842A (ja) *	2003-05-29	2007-03-08	ミレニアムファーマシューティカルズ，インコーポレイテッド	乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
EP1646648A2 (en) *	2003-07-15	2006-04-19	Genova Ltd.	Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
EP1760089B1 (en) *	2005-09-05	2009-08-19	Immatics Biotechnologies GmbH	Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
EP1806358B1 (en) *	2005-09-05	2010-03-17	Immatics Biotechnologies GmbH	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1795599A1 (en) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells

2005
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
2006
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
2007
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
HK1220709A1 (zh)	2017-05-12
US7833969B2 (en)	2010-11-16
AU2006289290B2 (en)	2010-11-25
AU2010236029B2 (en)	2012-06-28
US20080207520A1 (en)	2008-08-28
ES2302546T3 (es)	2008-07-16
DE602005005196D1 (de)	2008-04-17
ES2373907T3 (es)	2012-02-10
NZ588813A (en)	2011-06-30
PT1922335E (pt)	2010-03-03
PL1806358T3 (pl)	2010-08-31
US7807642B2 (en)	2010-10-05
WO2007028574A9 (en)	2008-05-02
KR101386790B1 (ko)	2014-04-21
PT1806358E (pt)	2010-05-28
EP1760088B1 (en)	2008-03-05
EA013876B1 (ru)	2010-08-30
ATE532795T1 (de)	2011-11-15
US20080206216A1 (en)	2008-08-28
ATE388164T1 (de)	2008-03-15
US10618945B2 (en)	2020-04-14
ATE461214T1 (de)	2010-04-15
AU2010236029A1 (en)	2010-11-18
CY1107973T1 (el)	2013-09-04
SI1806358T1 (sl)	2010-06-30
WO2007028574A2 (en)	2007-03-15
DE602006011030D1 (de)	2010-01-21
EP1806358A2 (en)	2007-07-11
US7833970B2 (en)	2010-11-16
EP2138509A1 (en)	2009-12-30
US20080206217A1 (en)	2008-08-28
KR101386355B1 (ko)	2014-04-17
EP2135878B1 (en)	2011-11-09
CY1109849T1 (el)	2014-09-10
HRP20110981T1 (hr)	2012-02-29
JP5627180B2 (ja)	2014-11-19
US20100040590A1 (en)	2010-02-18
KR101386827B1 (ko)	2014-04-17
PT1806359E (pt)	2010-05-25
US20160115212A1 (en)	2016-04-28
CY1112186T1 (el)	2015-12-09
PL2135878T3 (pl)	2012-06-29
CN103059104B (zh)	2015-10-28
PL1922335T3 (pl)	2010-05-31
PT2135878E (pt)	2012-01-05
EP1922335A2 (en)	2008-05-21
NZ566104A (en)	2011-04-29
WO2007028574A3 (en)	2007-05-24
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
DE602005020047D1 (de)	2010-04-29
AU2006289290A1 (en)	2007-03-15
KR20130019034A (ko)	2013-02-25
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
DK2135878T3 (da)	2012-02-27
HK1183678A1 (en)	2014-01-03
CN103059104A (zh)	2013-04-24
EP1806358B1 (en)	2010-03-17
NO20081683L (no)	2008-04-04
EP1760088A1 (en)	2007-03-07
DK1806358T3 (da)	2010-06-28
CN101287754A (zh)	2008-10-15
DK1806359T3 (da)	2010-06-14
KR20130019033A (ko)	2013-02-25
CA2621389A1 (en)	2007-03-15
DK1922335T3 (da)	2010-04-19
ATE451388T1 (de)	2009-12-15
EP1806358A3 (en)	2007-10-03
SI1806359T1 (sl)	2010-06-30
CA2929252A1 (en)	2007-03-15
CY1110187T1 (el)	2015-01-14
EP2135878A1 (en)	2009-12-23
EA200800677A1 (ru)	2008-08-29
UA98295C2 (ru)	2012-05-10
CN101287754B (zh)	2013-02-13
EP1806359A1 (en)	2007-07-11
EP1922335B1 (en)	2009-12-09
CA2621389C (en)	2016-07-19
US10196432B2 (en)	2019-02-05
ES2341295T3 (es)	2010-06-17
ATE461215T1 (de)	2010-04-15
HRP20100128T1 (hr)	2010-04-30
PT1760088E (pt)	2008-05-14
EP1806359B1 (en)	2010-03-17
DE602005020046D1 (de)	2010-04-29
CY1110051T1 (el)	2015-01-14
SI1760088T1 (sl)	2008-06-30
NO340870B1 (no)	2017-07-03
DE602005005196T2 (de)	2008-06-26
ES2337399T3 (es)	2010-04-23
SI1922335T1 (sl)	2010-04-30
SI2135878T1 (sl)	2012-03-30
ES2341802T3 (es)	2010-06-28
KR20080052643A (ko)	2008-06-11
US20080206218A1 (en)	2008-08-28
JP2010502173A (ja)	2010-01-28

Publication	Publication Date	Title
DK2135878T3 (da)	2012-02-27	Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
PL1760089T3 (pl)	2010-03-31	Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
SI1794190T1 (sl)	2009-12-31	Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope